Report No. DODIG-2017-046



INSPECTOR GENERAL

U.S. Department of Defense

JANUARY 30, 2017



Independent Auditor's Report on the FY 2016 DoD Detailed Accounting Report for the Funds Obligated for National Drug Control Program Activities

INTEGRITY \star EFFICIENCY \star ACCOUNTABILITY \star EXCELLENCE

Mission

Our mission is to provide independent, relevant, and timely oversight of the Department of Defense that supports the warfighter; promotes accountability, integrity, and efficiency; advises the Secretary of Defense and Congress; and informs the public.

Vision

Our vision is to be a model oversight organization in the Federal Government by leading change, speaking truth, and promoting excellence—a diverse organization, working together as one professional team, recognized as leaders in our field.



For more information about whistleblower protection, please see the inside back cover.



INSPECTOR GENERAL DEPARTMENT OF DEFENSE 4800 MARK CENTER DRIVE ALEXANDRIA, VIRGINIA 22350-1500

January 30, 2017

MEMORANDUM FOR UNDER SECRETARY OF DEFENSE (COMPTROLLER)/ CHIEF FINANCIAL OFFICER, DOD DEPUTY ASSISTANT SECRETARY OF DEFENSE (COUNTERNARCOTICS AND GLOBAL THREATS)

SUBJECT: Independent Auditor's Report on the FY 2016 DoD Detailed Accounting Report for the Funds Obligated for National Drug Control Program Activities (Project No. D2017-D000FT-0007.000, Report No. D0DIG-2017-046)

Public Law 105-277, title VII, "Office of National Drug Control Policy Reauthorization Act of 1998" (the Act), October 21, 1998, requires the DoD to submit a detailed report (the Report) each year to the Director, Office of National Drug Control Policy (ONDCP), accounting for all funds DoD expended for National Drug Control Program activities during the previous fiscal year. The Office of the Deputy Assistant Secretary of Defense for Counternarcotics and Global Threats (DASD[CN>]) compiles and transmits the Report. The Act also requires the DoD Office of Inspector General to authenticate the Report before it is submitted to the ONDCP Director (section 1704(d), title 21, United States Code).

The ONDCP Circular, "Accounting of Drug Control Funding and Performance Summary," January 18, 2013, (the Circular) provides the policies and procedures the DoD must use to prepare the Report and authenticate the DoD funds expended on National Drug Control Program activities. The Circular specifies that the Report must contain a table of prior-year drug-control obligations, listed by functional area, and include assertions relating to the obligation data presented in the table. The assertions are:

- use of actual obligations from accounting systems of record,
- reasonable and accurate drug methodology to calculate obligations by functional area,
- disclosure of actual drug methodology used,
- association with a financial plan, and
- compliance with Fund Control Notices issued by the ONDCP Director.

We performed this review-level attestation in accordance with attestation standards established by the American Institute of Certified Public Accountants and in compliance with generally accepted government auditing standards. Those standards require that we obtain sufficient evidence to provide a reasonable basis for our conclusions. We believe the evidence provided a reasonable basis for our conclusions based on our attestation objective. A review-level attestation is substantially less in scope than an examination done to express an opinion on the subject matter. Accordingly, we do not express an opinion.

We reviewed four DoD reprogramming actions that allocated \$1.24 billion among the Military Departments, the National Guard, and Defense agencies. We reviewed the yearend obligation report and determined that the DASD(CN>) allocated the funds to appropriations and project codes intended for the DoD Counterdrug Program.

The DASD(CN>) provided us the Report, dated November 30, 2016, which we reviewed to determine its compliance with the Circular. The detailed accounting indicated that during FY 2016, the DoD obligated \$1.14 billion to the Counterdrug Program functional areas. The DASD(CN>) compiled the Report from data submitted by the Military Departments and other DoD Components. The Report is attached.

The DASD(CN>) initially reprogrammed the funds from the Central Transfer Account to the DoD Components using project codes. The DoD Components provided yearend obligation data to the DASD(CN>) through the DASD(CN>) database, which compiled the data into one obligation report. To present the obligations by functional area as required by the Circular, the DASD(CN>) applied percentages to each project code in the consolidated report to calculate the amounts presented in the table of obligations instead of obtaining the information directly from the accounting systems.

Except for the DASD(CN>)'s use of percentages to calculate the obligations presented by functional area, nothing came to our attention during our review that caused us to believe the Report, or associated assertions, were not presented fairly, in all material respects, in conformity with the Circular.

Louin T. Venable


Lorin T. Venable, CPA Assistant Inspector General Financial Management and Reporting

Attachment: As stated

Attachment

DoD FY 2016 Counternarcotics Detailed Accounting Submission

OFFICE OF ASSISTANT SECRETARY OF DEFENSE 2500 DEFENSE PENTAGON WASHINGTON, D.C. 20301-2500 INTERIEN CONFLICT Mr. Scott Chronister NOV 3 0 2016 Office of Performance and Budget Office of National Drug Control Policy 750 17th Street, NW Room 535 Washington, DC 20503 Dear Mr. Chronister: This is the Department of Defense's (DoD) Detailed Accounting Submission for Fiscal Year 2016. The aggregate prior year drug control obligations data is at Tab A; the data was derived from actual obligations reports generated by the various accounting systems of record within DoD. The methodology used to generate all obligations data by drug control function is reasonable and accurate; the methodology used is enclosed at Tab B. The obligations data is associated with a financial plan that properly reflects all changes made during the fiscal year; ONDCP did not issue us any Fund Control Notices. My point of contact for this action is aren C. Hollis Caryn C. Hollis Deputy Assistant Secretary of Defense Counternarcotics and Global Threats Enclosures: As stated CF: DODIG



DoD FY 2016 Counternarcotics Detailed Accounting Submission (cont'd)

DoD FY 2016 Counternarcotics Detailed Accounting Submission (cont'd)

DRUG METHODOLOGY

Drug Interdiction and Counterdrug Activities, Defense

The purpose of this document is to explain the methodology used to express funding levels and calculate obligations of prior year budgetary resources in Department of Defense's (DoD) budget for counterdrug activities in terms of the drug control functions in the National Drug Control Budget. As background, DoD's dedicated budget for counterdrug activities is a transfer account titled Drug Interdiction and Counterdrug Activities. Congress appropriates funds into this account, and the funds are subsequently transferred to the various Military Departments and select Defense Agencies for execution. As designed, the transfer account serves to provide centralized management and decentralized execution.

The account is structured into various project codes, each designed to either provide a discrete function, or to isolate similar functions by the various geographic combatant commands; however, although the account's entire funding levels are drug-related, it is <u>not</u> structured by the drug control functions of the National Drug Control Budget. In order to reasonably and fairly quantify the account's financial commitment in terms of the drug control functions, each project code is cross-walked to one or more drug control functions, either in its entirety or proportionally, using an interactive database for financial management. This methodology provides a reasonable basis for consistently estimating and translating our funding levels into the drug control functions.

The separate Military Departments and Defense Agencies use their own accounting systems of record for tracking obligations of funds transferred from the Drug Interdiction and Counterdrug Activities appropriations. These distinct accounting systems do not interface directly with the counterdrug financial management database; the Military Departments and Defense Agencies manually enter obligations by project code to this database on a quarterly basis. At the end of each fiscal, the Military Departments and Defense Agencies submit transaction listings of actual obligations data, which are compared to the aggregate data in the database. The aggregate data is compiled into a single obligations report by drug control functions, using the project code-to-drug control function cross-walk described above; the report further informs the Detailed Accounting Submission and Annual Statement of Assurance to ONDCP.

Tab B



Whistleblower Protection U.S. Department of Defense

The Whistleblower Protection Ombudsman's role is to educate agency employees about prohibitions on retaliation and employees' rights and remedies available for reprisal. The DoD Hotline Director is the designated ombudsman. For more information, please visit the Whistleblower webpage at www.dodig.mil/programs/whistleblower.

For more information about DoD OIG reports or activities, please contact us:

Congressional Liaison congressional@dodig.mil; 703.604.8324

Media Contact public.affairs@dodig.mil; 703.604.8324

For Report Notifications www.dodig.mil/pubs/email_update.cfm

> Twitter www.twitter.com/DoD_IG

DoD Hotline www.dodig.mil/hotline



DEPARTMENT OF DEFENSE | INSPECTOR GENERAL

4800 Mark Center Drive Alexandria, VA 22350-1500 www.dodig.mil Defense Hotline 1.800.424.9098

